MILKA NDUNGU: Open Payments
NPI 1538431739 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 23 payments from 16 companies in 2025. Trend: 2023 $709 · 2024 $876 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $81 |
| AstraZeneca Pharmaceuticals LP | 3 | $74 |
| Mallinckrodt Hospital Products Inc. | 3 | $67 |
| Amgen Inc. | 2 | $39 |
| Calliditas Therapeutics US Inc. | 1 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Veloxis Pharmaceuticals, Inc. | 1 | $29 |
| CorMedix Inc. | 1 | $25 |
| KYOWA KIRIN, INC. | 1 | $25 |
Products named: PREVYMIS, FARXIGA, ACTHAR, TAVNEOS, TARPEYO, GIVLAARI, ENVARSUS, DEFENCATH.
Industry payments across TX — which companies pay providers there.
